RxDoctor Payments Data

Emily Baker, APRN

Clinical Nurse Specialist · Austin, TXNPI 1568066413

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 42.8% of the total.

$545in general payments, 2019–2025

Across 13 payments — averaging $41.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$234
  • Pfizer$90
  • Argenx US, Inc.$49
  • Teva Pharmaceuticals USA, Inc.$49
  • GRT US Holding, Inc.$32
  • Arbor Pharmaceuticals, Inc.$31
  • plus $61 from 3 others

What the payments were for

  • Food & beverage$545100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$545 in reported general payments places this provider in the 60th percentile of 88 clinical nurse specialist providers in Texas.

See all clinical nurse specialist providers in Texas

Medicare billing

Part B allowed, 2024
$43,874
Medicare patients
85
Services billed
4,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate61$108,433
QuliptaAtogepant56$68,563
UbrelvyUbrogepant26$41,280
BotoxOnabotulinumtoxina21$26,745
Ajovy AutoinjectorFremanezumab-Vfrm20$14,827
Aimovig AutoinjectorErenumab-Aooe16$13,893
Emgality PenGalcanezumab-Gnlm14$11,872
Rivastigmine15$7,537
Memantine Hcl ErMemantine Hcl25$5,081
Sumatriptan Succinate25$2,079
Gabapentin98$1,787
Levetiracetam35$1,255
Memantine Hcl74$995
RivastigmineRivastigmine Tartrate15$970
Zonisamide16$940

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy, Botox$234$136,588103 claims
PfizerNurtec Odt$90$108,43361 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 88 clinical nurse specialist providers in Texas.

Other clinical nurse specialist in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →